LITTLE FALLS, N.J.,
June 6, 2013 /PRNewswire/ --
CANTEL MEDICAL CORP. (NYSE: CMN) reported a 10% increase in
net income to $8,998,000, or
$0.33 per diluted share, on an 8%
increase in sales to $105,009,000 for
the third quarter ended April 30,
2013. This compares with net income of $8,174,000, or $0.30 per diluted share, on sales of $97,238,000 for the third quarter ended
April 30, 2012. For the nine months
ended April 30, 2013, the Company
reported record net income of $29,026,000, or $1.06 per diluted share, inclusive of
$0.02 in net favorable adjustments
related to acquisition accounting partially offset by severance and
recruiting costs, on an 8% increase in sales to a record
$311,053,000. This compares
with net income of $21,688,000 or
$0.80 per diluted share, inclusive of
a $0.02 charge related to an asset
impairment, on sales of $287,797,000
for the nine months ended April 30,
2012.
Andrew Krakauer, Cantel's
President and CEO stated, "We are pleased to have delivered solid
financial performance in the third quarter. These positive results
confirm the continued success of our three prong approach to growth
which includes investing in new product development, sales and
marketing programs and acquisitions. Reported earnings would have
been $0.02 better if not for the
Medical Device Tax which impacted all three months of this
quarter."
Krakauer added, "Performance this quarter was led by our
Healthcare Disposables segment. With the benefit of the ongoing
integration of the SPS Medical sterility assurance business
acquired on November 1, 2012, sales
in this segment grew by 17% compared to last year and we were able
to offset the negative effect caused by our distributors pulling
forward shipments last quarter. Operating profits were 13% higher
and grew more slowly than sales as we made substantial investments
in sales and marketing expenses. We are very pleased with the
performance of SPS Medical and will be investing in additional
sales and marketing resources, as well as R&D, to accelerate
growth in fiscal year 2014 and beyond.
As in the first two quarters of this fiscal year, our Water
Purification and Filtration segment had excellent year-over-year
quarterly performance with organic sales growth of almost 14%.
Operating profits in this segment were only slightly higher due to
increases in selling expenses and transaction expenses associated
with our recent acquisition. In our largest business unit,
Endoscopy, quarterly sales growth of 3% was driven by our liquid
chemical germicides, service and procedural products categories. We
remain encouraged with the continued growth prospects for this
segment as we continue to launch new products into this
multi-billion market segment. At two major endoscopy trade
shows in May, we had a very successful turnout and were encouraged
by the customer excitement and feedback on our portfolio of newly
launched products."
The Company further reported that its balance sheet at
April 30, 2013 included current
assets of $145,183,000, including
cash of $30,669,000, a current ratio
of 2.6:1, debt of $105,000,000 and
stockholders' equity of $307,955,000. Krakauer stated, "The Company
has a strong balance sheet and continues to generate significant
cash flow and EBITDAS. When compared with the first nine
months of last year, our EBITDAS grew by 19% to $62,806,000. Net debt was reduced during
the quarter by almost $6 million to
$74,331,000 despite the approximate $8 million acquisition of the Siemens
hemodialysis water business announced on March 25."
Cantel Medical Corp. (NYSE: CMN) is a leading provider of
infection prevention and control products in the healthcare market.
Our products include water purification equipment, sterilants,
disinfectants and cleaners, specialized medical device reprocessing
systems for endoscopy and renal dialysis, disposable infection
control products primarily for dental and GI endoscopy markets,
dialysate concentrates and other dialysis supplies, hollow fiber
membrane filtration and separation products for medical and
non-medical applications, and specialty packaging for infectious
and biological specimens. We also provide technical maintenance for
our products and offer compliance training services for the
transport of infectious and biological specimens.
The Company will hold a conference call to discuss the results
for the third quarter ended April 30,
2013 on Thursday, June 6, 2013
at 11:00 AM Eastern time. To
participate in the conference call, dial 1-877-407-8033
approximately 5 to 10 minutes before the beginning of the call. If
you are unable to participate, a digital replay of the call will be
available from Thursday, June 6, 2013
at 2:00 PM through midnight on
August 6, 2013 by dialing
1-877-660-6853 and using conference ID #415610.
The call will be simultaneously broadcast live over the Internet
on vcall.com at
http://www.investorcalendar.com/IC/CEPage.asp?ID=171058. A replay
of the webcast will be available on Vcall for 90 days.
For further information, visit the Cantel website at
www.cantelmedical.com.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements involve a number of risks and uncertainties,
including, without limitation, the risks detailed in Cantel's
filings and reports with the Securities and Exchange Commission.
Such forward-looking statements are only predictions, and actual
events or results may differ materially from those projected or
anticipated.
CANTEL MEDICAL
CORP.
|
CONDENSED
CONSOLIDATED STATEMENTS OF INCOME
|
(In thousands, except
per share data)
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
|
|
Nine Months
Ended
|
|
|
April 30,
|
|
April 30,
|
|
|
2013
|
|
2012
|
|
2013
|
|
2012
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
$
105,009
|
|
$
97,238
|
|
$
311,053
|
|
$
287,797
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
|
59,525
|
|
54,619
|
|
176,691
|
|
166,407
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
|
45,484
|
|
42,619
|
|
134,362
|
|
121,390
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
Selling
|
|
15,096
|
|
14,240
|
|
42,232
|
|
40,433
|
General and
administrative
|
|
13,766
|
|
12,388
|
|
38,196
|
|
36,582
|
Research and
development
|
|
2,399
|
|
2,217
|
|
6,876
|
|
6,660
|
Total operating
expenses
|
|
31,261
|
|
28,845
|
|
87,304
|
|
83,675
|
|
|
|
|
|
|
|
|
|
Income before
interest, other expense and income taxes
|
14,223
|
|
13,774
|
|
47,058
|
|
37,715
|
|
|
|
|
|
|
|
|
|
Interest
expense
|
|
749
|
|
897
|
|
2,186
|
|
2,928
|
Interest
income
|
|
(16)
|
|
(13)
|
|
(45)
|
|
(67)
|
Other
expense
|
|
-
|
|
-
|
|
-
|
|
605
|
|
|
|
|
|
|
|
|
|
Income before income
taxes
|
|
13,490
|
|
12,890
|
|
44,917
|
|
34,249
|
|
|
|
|
|
|
|
|
|
Income
taxes
|
|
4,492
|
|
4,716
|
|
15,891
|
|
12,561
|
|
|
|
|
|
|
|
|
|
Net
income
|
|
$
8,998
|
|
$
8,174
|
|
$
29,026
|
|
$
21,688
|
|
|
|
|
|
|
|
|
|
Earnings per common
share - diluted
|
|
$
0.33
|
|
$
0.30
|
|
$
1.06
|
|
$
0.80
|
|
|
|
|
|
|
|
|
|
Dividends per common
share
|
|
$
-
|
|
$
-
|
|
$
0.06
|
|
$
0.05
|
|
|
|
|
|
|
|
|
|
Weighted average
shares - diluted
|
|
27,501
|
|
27,282
|
|
27,442
|
|
27,148
|
|
|
|
|
|
CANTEL MEDICAL
CORP.
|
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
(In
thousands)
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
April 30,
|
|
July 31,
|
|
|
2013
|
|
2012
|
Assets
|
|
|
|
|
Current assets
|
|
$
145,183
|
|
$
133,892
|
Property and equipment,
net
|
|
45,431
|
|
43,022
|
Intangible assets,
net
|
|
74,165
|
|
71,311
|
Goodwill
|
|
208,176
|
|
183,655
|
Other assets
|
|
11,409
|
|
2,932
|
|
|
$
484,364
|
|
$
434,812
|
|
|
|
|
|
Liabilities and stockholders' equity
|
|
|
|
Current portion of long-term
debt
|
|
$
10,000
|
|
$
10,000
|
Other current
liabilities
|
|
46,260
|
|
45,141
|
Long-term debt
|
|
95,000
|
|
80,000
|
Other long-term
liabilities
|
|
25,149
|
|
23,735
|
Stockholders'
equity
|
|
307,955
|
|
275,936
|
|
|
$
484,364
|
|
$
434,812
|
|
|
|
|
|
SUPPLEMENTARY
INFORMATION
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of
Earnings Before Interest, Taxes, Depreciation, Amortization and
Stock-Based
|
|
|
Compensation
Expense ("EBITDAS")
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
The reconciliation of
EBITDAS with net income for the three and nine months ended April
30, 2013 and 2012,
|
|
respectively, is as
follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
|
|
Nine Months
Ended
|
|
|
|
April 30,
|
|
April 30,
|
|
|
|
2013
|
|
2012
|
|
2013
|
|
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
8,998
|
|
$
8,174
|
|
$
29,026
|
|
$
21,688
|
|
|
|
|
|
|
|
|
|
|
|
Income
taxes
|
|
4,492
|
|
4,716
|
|
15,891
|
|
12,561
|
|
Interest
expense
|
|
749
|
|
897
|
|
2,186
|
|
2,928
|
|
Interest
income
|
|
(16)
|
|
(13)
|
|
(45)
|
|
(67)
|
|
Other
expense
|
|
-
|
|
-
|
|
-
|
|
605
|
|
Depreciation
|
|
1,806
|
|
1,735
|
|
5,380
|
|
5,129
|
|
Amortization
|
|
2,598
|
|
2,279
|
|
7,438
|
|
6,846
|
|
Loss (gain) on
disposal of fixed assets
|
|
(16)
|
|
58
|
|
124
|
|
94
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA
|
|
18,611
|
|
17,846
|
|
60,000
|
|
49,784
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based
compensation expense
|
|
919
|
|
706
|
|
2,806
|
|
3,019
|
|
|
|
|
|
|
|
|
|
|
|
EBITDAS
|
|
$
19,530
|
|
$
18,552
|
|
$
62,806
|
|
$
52,803
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDAS is a measure
of the Company's performance that is not required by, or presented
in accordance with,
|
|
Generally Accepted
Accounting Principles ("GAAP"). EBITDAS is a non-GAAP financial
measure defined by the
|
|
Company as income
before interest, taxes, depreciation, amortization and stock-based
compensation expense.
|
|
The Company believes
EBITDAS is an important valuation measurement for management and
investors given
|
|
the increasing effect
that non-cash charges, such as stock-based compensation,
amortization related to acquisitions
|
|
and depreciation of
capital equipment, has on the Company's net income. In particular,
acquisitions have historically
|
|
resulted in
significant increases in amortization of intangible assets that
reduced the Company's net income.
|
|
Additionally, the
Company regards EBITDAS as a useful measure of operating
performance and cash flow before
|
|
the effect of
interest expense and complements operating income, net income and
other GAAP financial
|
|
|
performance measures.
Generally, a non-GAAP financial measure is a numerical measure of a
Company's
|
|
performance,
financial position or cash flow that either excludes or includes
amounts that are not normally excluded
|
|
or included in the
most directly comparable measure calculated and presented in
accordance with GAAP.
|
|
|
This measure,
however, should be considered in addition to, and not as a
substitute or superior to, net income,
|
|
cash flows, or other
measures of financial performance prepared in accordance with
GAAP.
|
|
|
|
SOURCE Cantel Medical Corp.